Comparative analysis of systemic oncological treatments and best supportive care for advanced gastresophageal cancer: A comprehensive scoping review and evidence map

被引:1
作者
Marilina, Santero [1 ]
Adriana, Meade [1 ]
Anna, Selva [1 ,2 ]
Roberto, Acosta-Dighero [3 ]
Nicolas, Meza [4 ]
Jesus, Quintana Maria [1 ]
Javier, Bracchiglione [1 ,4 ]
Carolina, Requeijo [1 ]
Josefina, Salazar [1 ]
Gerardo, Rodriguez Grijalva [1 ]
Ivan, Sola [1 ,5 ]
Gerard, Urrutia [1 ,5 ]
Xavier, Bonfill Cosp [1 ,5 ,6 ]
机构
[1] Biomed Res Inst St Pau IIB St Pau, Iberoamer Cochrane Ctr, Barcelona, Spain
[2] Univ Autonoma Barcelona, Parc Tauli Hosp Univ, Inst Invest & Innovacio Parc Tauli I3PT CERCA, Clin Epidemiol & Canc Screening, Sabadell, Spain
[3] Univ Chile, Fac Med, Dept Phys Therapy, Santiago, Chile
[4] Univ Valparaiso, Interdisciplinary Ctr Hlth Studies CIESAL, Vina Del Mar, Chile
[5] CIBER, CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain
[6] Univ Autonoma Barcelona, Dept Paediat Obstet & Gynaecol & Prevent Med & Pu, Barcelona, Spain
关键词
drug therapy; esophageal neoplasms; immunotherapy; molecular targeted therapy; review; stomach neoplasms; ADVANCED GASTRIC-CANCER; ADVANCED ESOPHAGOGASTRIC CANCER; ADVANCED ESOPHAGEAL CANCER; SQUAMOUS-CELL CARCINOMA; SEOM CLINICAL GUIDELINE; RANDOMIZED PHASE-III; QUALITY-OF-LIFE; DOUBLE-BLIND; SALVAGE CHEMOTHERAPY; PALLIATIVE CHEMOTHERAPY;
D O I
10.1111/jebm.12539
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveTo identify, describe, and organize the available evidence regarding systemic oncological treatments compared to best supportive care (BSC) for advanced gastresophageal cancer. MethodsWe conducted a thorough search across MEDLINE (PubMed), EMbase (Ovid), The Cochrane Library, Epistemonikos, PROSPERO, and Clinicaltrials.gov. Our inclusion criteria encompassed systematic reviews, randomized controlled trials, quasi-experimental and observational studies involving patients with advanced esophageal or gastric cancer receiving chemotherapy, immunotherapy or biological/targeted therapy compared to BSC. The outcomes included survival, quality of life, functional status, toxicity, and quality of end-of-life care. ResultsWe included and mapped 72 studies, comprising SRs, experimental and observational designs, 12 on esophageal cancer, 51 on gastric cancer, and 10 both locations. Most compared schemes including chemotherapy (47 studies), but did not report therapeutic lines. Moreover, BSC as a control arm was poorly defined, including integral support and placebo. Data favor the use of systemic oncological treatments in survival outcomes and BSC in toxicity. Data for outcomes including quality of life, functional status, and quality of end-of-life care were limited. We found sundry evidence gaps specifically in assessing new treatments such as immunotherapy and important outcomes such as functional status, symptoms control, hospital admissions, and the quality of end-life care for all the treatments. ConclusionsThere are important evidence gaps regarding new for patients with advanced gastresophageal cancer and the effect of systemic oncological treatments on important patient-centered outcomes beyond survival. Future research should clearly describe the population included, specifying previous treatments and considering therapeutic, and consider all patient-centered outcomes. Otherwise, it will be complex to apply research results into practice.
引用
收藏
页码:216 / 236
页数:21
相关论文
共 132 条
  • [1] Palliative Chemotherapy Does Not Improve Survival in Metastatic Esophageal Cancer
    Adenis, Antoine
    Penel, Nicolas
    Horn, Samy
    Dominguez, Sophie
    Vanhuyse, Marie
    Mirabel, Xavier
    [J]. ONCOLOGY, 2010, 79 (1-2) : 46 - 54
  • [2] Evidence Mapping of the Treatments for Breast Cancer-related Lymphedema
    Al-Sakkaf, Ali M.
    Masia, Jaume
    Auladell-Rispau, Ariadna
    Shamardal, Aliaa, I
    Vasconcello-Castillo, Luis
    Sola, Ivan
    Bonfill, Xavier
    [J]. PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN, 2022, 10 (01) : E4045
  • [3] SEVERE COMPLICATIONS OF 5-FLUOROURACIL AND CISPLATIN WITH CONCOMITANT RADIOTHERAPY IN INOPERABLE NONMETASTATIC SQUAMOUS-CELL ESOPHAGEAL CANCER AFTER INTUBATION - EARLY TERMINATION OF A PROSPECTIVE RANDOMIZED TRIAL
    ALBERTS, AS
    BURGER, W
    GREEFF, F
    SCHOEMAN, L
    FRIEDIGER, D
    NEL, J
    STEYN, E
    SCHMID, EU
    FALKSON, G
    [J]. EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) : 1005 - 1006
  • [4] Alkhaffaf B., 2021, BRIT J SURG
  • [5] Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives
    Alonso-Coello, Pablo
    Montori, Victor M.
    Diaz, M. Gloria
    Devereaux, Philip J.
    Mas, Gemma
    Diez, Ana I.
    Sola, Ivan
    Roura, Merce
    Souto, Juan C.
    Oliver, Sven
    Ruiz, Rafael
    Coll-Vinent, Blanca
    Gich, Ignasi
    Schuenemann, Holger J.
    Guyatt, Gordon
    [J]. HEALTH EXPECTATIONS, 2015, 18 (06) : 2318 - 2327
  • [6] [Anonymous], PHASE 3 STUDY XELOX
  • [7] [Anonymous], ?About us"
  • [8] Arksey H., 2007, INT J SOC RES METHOD, V8, P19, DOI [10.1080/1364557032000119616, DOI 10.1080/1364557032000119616]
  • [9] Development of a Core Outcome Set for Clinical Effectiveness Trials in Esophageal Cancer Resection Surgery
    Avery, Kerry N. L.
    Chalmers, Katy A.
    Brookes, Sara T.
    Blencowe, Natalie S.
    Coulman, Karen
    Whale, Katie
    Metcalfe, Chris
    Blazeby, Jane M.
    [J]. ANNALS OF SURGERY, 2018, 267 (04) : 700 - 710
  • [10] Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST)
    Ballesteros, Monica
    Montero, Nadia
    Lopez-Pousa, Antonio
    Urrutia, Gerard
    Sola, Ivan
    Rada, Gabriel
    Pardo-Hernandez, Hector
    Bonfill, Xavier
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2017, 17